Posted by Michael Wonder on 04 Apr 2025
Janssen Korea’s Zytiga secures expanded reimbursement for first-line prostate cancer treatment
2 April 2025 - Beginning in April, Janssen Korea's prostate cancer drug Zytiga will be available with prednisolone as a first-line treatment for patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer, with the patient’s out of pocket payment reduced from 30% (selective reimbursement) to 5%.
Janssen Korea announced that, effective 1 April, Zytiga will be reimbursed with a 5% co-payment for patients with metastatic castration-resistant prostate cancer who have an ECOG performance status of 0 or 1 and experience no or mild pain that does not require narcotic analgesics.
